Navigation Links
Surveyed Oncologists Indicate that the Use of Biomarker Testing is Increasing Rapidly in Non-Small-Cell Lung Cancer in China and South Korea
Date:12/5/2013

BURLINGTON, Mass., Dec. 5, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-small-cell lung cancer (NSCLC), biomarker testing is already widely employed in the China and South Korea markets, and is set to increase to European levels in the next two years.

(Logo:  http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

Decision Resources' new Emerging Markets Physician & Payer Forum report entitled NSCLC in China and South Korea: Physician and Payer Perspectives on Prescribing Trends, Patient Access, and Reimbursement Challenges Facing Current and Emerging Therapies finds that surveyed oncologists in China (most of whom practice in Tier 3 hospitals) estimate that one-half of their NSCLC patients are currently tested for EGFR mutations, and that by year-end 2016 almost three-quarters will be tested. ALK–translocation testing rates are currently low, at around one-fifth of patients, but will increase even more dramatically in the next three years. Pfizer's Xalkori, an oral, dual inhibitor of ALK and c-Met, was the first targeted agent to be approved for NSCLC with a companion diagnostic test. On the basis of impressive overall response data, Xalkori received regulatory approval in China in January 2013 and became available in a number of regions about six months later. Lack of reimbursement for testing and the high cost treatment are the key barriers to testing in China, but surveyed oncologists also point to lack of patient willingness to be tested.

In South Korea, the EGFR-mutation testing rate is already comparable with Europe as 69 percent of survey respondents' patients are currently tested, and such testing is expected to increase to 80 percent by year-end 2016, despite the lack of reimbursement by the National Health Insurance.

The report also finds that in China, inclusion in the NRDL—China's national formulary—is key to securing reimbursement and widespread uptake; however, no NSCLC targeted agents are included in the current list, and interviewed payers do not expect targeted agents to be included in the next version of the NRDL, due for publication in 2014.

"Coverage of targeted agents on the 30-plus provincial formularies, the PRDLs, is patchy," said Decision Resources Product Director Andreia Ribeiro, Ph.D. "However, payers report that provinces with surplus funds sometimes agree to reimburse agents without formal PRDL inclusion. PRDLs are prepared in the year following NRDL publication so 2014/2015 will be the window of opportunity for companies to negotiate PRDL listing. Access to targeted agents has been accomplished at the municipal level for certain brands; marketers have been successful in striking deals with social security bureaus in prosperous eastern cities with sufficient budgets to underwrite local reimbursement schemes." 

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. According to Surveyed EU5 Oncologists, Zelboraf Captures 50 Percent Patient Share of the First-Line BRAF-Mutation Positive Malignant Melanoma Population
2. According to Surveyed U.S. Oncologists, Zelboraf is the Patient Share Leader in First-Line BRAF-Mutation Positive Malignant Melanoma
3. Surveyed Endocrinologists Consider Eli Lillys Dulaglutide To Have an Edge Over Competitors for the Treatment of Type 2 Diabetes Patients Who Are Inadequately Controlled On Metformin
4. Two-Thirds of Surveyed U.S. Neurologists Have Prescribed Genzymes Aubagio to Their Multiple Sclerosis Patients at One Year Post-Launch
5. Surveyed EU5 Rheumatologists Prescribe Biologics to Approximately Half of Their DMARD-Treated Psoriatic Arthritis Patients
6. Surveyed EU5 Oncologists Plan Increased Uptake of Perjeta for HER2-Positive Breast Cancer, But Expect Reimbursement Hurdles for Perjeta Plus Kadcycla
7. Surveyed Physicians Report that Invokana Captures a Small Percentage of Patient Share in the Type 2 Diabetes Drug Market, With Significant Increases Expected Six Months from Now
8. Surveyed U.S. Rheumatologists are Moderately Satisfied with Biologic Agents and Xeljanz to Treat Rheumatoid Arthritis
9. More than a Third of Chronic Kidney Disease-Non-Dialysis Patients are Likely Candidates for FG-4592/ASP1517, According to Surveyed EU5 Nephrologists
10. At One Month Post-Launch, Nearly a Quarter of Surveyed U.S. Oncologists Have Prescribed Tafinlar for Malignant Melanoma, Compared to 15 Percent Who Used Mekinist
11. Should Mircera Reach the U.S. Market, Surveyed Nephrologists State that at Least 40 Percent of CKD-ND and Dialysis Patients are Likely Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... 13, 2017 It should come as no surprise ... is in the midst of a crippling opioid epidemic. According ... the number of overdose deaths from opiate-based medications has quadrupled, ... a million dead from 2001 to 2015". During this time, ... has similarly quadrupled, drawing a compelling link between prescription and ...
(Date:7/13/2017)... 2017 RK Logistics Group, Inc. was awarded ... its Fremont, CA headquarters facility where ... and San Jose for hi-tech, pharmaceutical ... , with its Fremont Innovation District, is excited to ... powerful resource to the hundreds of biotech, pharma and biomed ...
(Date:7/12/2017)... -- CarpalAID is a revolutionary new product that relieves painful carpal ... tunnel syndrome affects more than 8 million people a year. Women ... The common methods of treating CTS are painful surgery, the use ... gloves. ... CarpalAID is a clear patch worn on the palm of the ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... 21, 2017 , ... In the first prospective ACL reconstruction ... Outcome Network (MOON) demonstrated that patients could perform sports-related functions and maintain a ... over time. The study, presented today at the American Orthopaedic Society for ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... rates are on the rise, say researchers presenting their work at the ... Canada. , “The combination of evaluating the patterns of change in concussion symptom ...
(Date:7/20/2017)... Richmond, Va. (PRWEB) , ... July 20, 2017 , ... ... Daniel McCarter, MD, has joined JenCare Senior Medical Center as Richmond Chief ... of Virginia School of Medicine, and Associate Chief Medical Officer of Ambulatory Services for ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... and application performance monitoring (APM) solutions, has expanded its footprint inside the ... According to Peter Ohrenberger, sales director at Nastel, “We’ve replaced an existing ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... For individuals ... utmost importance. The adjustable beds used in such facilities are specially designed to accommodate ... adequate arm support. , An inventor from Rochester, Ind., has invented the patent-pending ...
Breaking Medicine News(10 mins):